ジャパン・ティッシュ・エンジニアリング（7774） – 10th Technology and Management/Innovation Award -METI Minister’s Award- Winner

January. 26, 2022 Japan Tissue Engineering Co., Ltd. 10th Technology and Management/Innovation Award “METI Minister’s Award” Winner “Popularization of Japan’s First Regenerative Medical Product – Autologous Cultured Epidermis JACE®” Japan Tissue Engineering Co., Ltd. (headquartered in Gamagori, Aichi. CEO: Kenichiro Hata) has announced today of being awarded “METI Minister’s Award” in the 10th Technology and Management/Innovation Award held by Japan Techno-Economics Society (with the support of MIC, MEXT, METI, Nikkei Inc., Nikkan Kogyo Shimbun, Ltd.) for “the popularization of Japan’s first regenerative medical product, Autologous Cultured Epidermis JACE.” The Technology and Management/Innovation Award provides recognition to great innovative examples that have greatly revolutionized the world. The purpose of the award is to introduce technological and social changes or innovations that are about to cause said changes and their practical processes to provide a reference point for the next generation of management and engineers to promote further innovation. The award was prompted through the recognition of “the popularization of Japan’s first regenerative medical product, Autologous Cultured Epidermis JACE” which has become the gold standard for difficult-to-treat severe burns, contributing to the saving of lives for many patients, its establishment of creating a stable supply structure in cooperation with medical facilities, as well as through over 1,000 successful transplants. [The award details are as follows] Awarded Organization Japan Tissue Engineering Co., Ltd. Enterprise Name Popularization of Japan’s First Regenerative Medical Product, Autologous Cultured Epidermis JACE Summary first The Autologous Cultured Epidermis JACE, (heretofore known as JACE) cultures the patient’s own skin cells to fabricate an epidermal cell sheet for transplant use. This is Japan’s regenerative medical product and has been approved in 2007 for production and sale for use with extensive severe burn treatment as well as being prescribed for by insurance in 2009 (Fig. 1). Afterwards, medical facilities and patient advocacy groups have expressed a strong demand for it, leading to expanding of approval for use on congenital melanocytic nevus in 2016 and epidermolysis bullosa in 2018. JACE has greatly contributed to saving the lives of and improving the quality of life for patients with refractory conditions. This has been used for the treatment of a variety of severe burn patients from incidents such as the 2013 Fukuchiyama fireworks accident, 2015 New Taipei water park fire, 2019 Fig. 1 Autologous Cultured Epidermis JACE Japan Tissue Engineering Co., Ltd., 6-209-1 Miyakitadori, Gamagori, Aichi 443-0022, Japan. URL: https://www.jpte.co.jp 1/2 Kyoto arson attack. It has become popularized for as a standard treatment procedure domestically as well as becoming highly regarded when provided as international support. JACE has been in development since the times when our nation’s pharmaceutical administration did not have a category for regenerative medicine. It has received pharmaceutical approval as a medical device, but the 2014 amendment to the Pharmaceutical Affairs Law created a new category for regenerative medical products, and thus, it was renamed as Japan’s first regenerative medical product. The development of JACE has not only opened the door to the heavily regulated Pharmaceutical Affairs Law, but also promoted the possibilities of regenerative medicine industry of our nation, building foundation of regenerative medicine development where Japan leads in the world. the Our company will continue to aim towards the goal of “Creating a Future for Regenerative Medicine” and to improve the patient quality of life. List of award winners for the “10th Technology and Management/Innovation Award”: (The information is in Japanese) https://www.jates.or.jp/management_study/management_of_technology_meeting/gikei_innovation_201607/10th_Kettei.html (Reference: About J-TEC) J-TEC is a maker of regenerative medical products whose corporate vision is “creating a future for regenerative medicine”. J-TEC is a member of the Teijin Group. As Japan’s top runner in regenerative medicine, J-TEC obtained marketing approval for autologous cultured epidermis “JACE”, Japan’s first regenerative medical product, in October of 2007, and began marketing the product in January of 2009. J-TEC then went on to obtain marketing approval for Autologous Cultured Cartilage “JACC” in July of 2021, for Autologous Cultured Corneal Epithelium “Nepic” in March of 2020, and for Autologous Cultured Oral Mucosal Epithelium “Ocural” in June 2021. “JACC” was Japan’s first regenerative medical product for use in orthopedic surgery, and “Nepic” was the first for use in ophthalmology. Of the 16 regenerative medical products that have been approved in Japan, four are J-TEC products. [Contact information for inquiries about this announcement] Japan Tissue Engineering Co., Ltd. Business Planning Department 0533-66-2020 TEL E-mail jtec-info@jpte.co.jp Japan Tissue Engineering Co., Ltd., 6-209-1 Miyakitadori, Gamagori, Aichi 443-0022, Japan. URL: https://www.jpte.co.jp 2/2